

The attention of the Office is called to the limitation in claims 12 and 17, the independent claims from which the remaining claims depend, that the pharmaceutical composition is intended for treating multiple sclerosis. Applicants wish to amend claims 12 and 17 as follows:

**Amendment**

**Amendments to the claims:**

---

1. (original): A method of treating multiple sclerosis (MS), including the step of administering to an individual a pharmaceutically-effective amount of cpn10 and IFN- $\beta$
2. (original): The method of claim 1, when used as a treatment to prevent relapse of MS.
3. (previously amended): The method of claim 1, wherein IFN- $\beta$  and cpn10 are administered together.
4. (previously amended): The method of claim 1, wherein IFN- $\beta$  and cpn10 are administered separately.
5. (original): The method of claim 3, wherein IFN- $\beta$  and cpn10 are administered by injection.
6. (original): The method of claim 4, wherein cpn10 is administered orally.
7. (previously amended): The method of claim 4, wherein IFN- $\beta$  is administered by injection.
8. (previously amended): The process of claim 1, wherein the pharmaceutically effective amount of cpn10 and IFN- $\beta$  comprises 5-60 mg of cpn10..

9. (original): The method of claim 8, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 10-30 mg of cpn10.

10. (previously amended): The method of claim 1, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 1-10 Million International Units (MIU) of IFN- $\beta$ .

11. (original): The method of claim 10, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 4-6 (MIU) of IFN- $\beta$ .

B1 12. (currently amended): A pharmaceutical composition for treating MS, wherein said composition ~~comprising a pharmaceutically-effective~~ an amount of cpn10 and of IFN- $\beta$  and a effective to treat MS in combination with a pharmaceutically-acceptable carrier or diluent.

13. (original): The composition of claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 5-60 mg of cpn10.

14. (original): The composition of claim 13, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 10-30 mg of cpn10.

15. (original): The composition of claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 1-10 MIU of IFN- $\beta$ .

16. (original): The composition of claim 15, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 4-6 MIU of IFN- $\beta$ .

17. (currently amended): A kit comprising ~~a pharmaceutically-effective~~ an amount of cpn10 and IFN- $\beta$  effective to treat MS and, in a separate container, and a pharmaceutically-acceptable carrier or diluent.

18. (original): The kit of claim 17, wherein said IFN- $\beta$  is in dehydrated form, which in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

19. (original): The kit of claim 18, wherein said cpn10 is in dehydrated form and in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

20. (previously amended): The kit of claim 17, wherein said cpn10 is in tablet or capsule form.

21. (original): The kit of claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 5-60 mg of cpn10.

22. (original): The kit of claim 21, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 10-30 mg of cpn10.

23. (original): The kit of claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 1-10 MIU of IFN- $\beta$ .

24. (original): The kit of claim 23, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 4-6 MIU of IFN- $\beta$ .

---